Free Trial

GT Biopharma (GTBP) Short Interest Ratio & Short Volume

GT Biopharma logo
$3.09 -0.10 (-3.13%)
(As of 10:31 AM ET)

GT Biopharma Short Interest Data

GT Biopharma (GTBP) has a short interest of 17,700 shares, representing 0.90% of the float (the number of shares available for trading by the public). This marks a 70.19% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.1, indicating that it would take 1.1 days of the average trading volume of 398,508 shares to cover all short positions.

Current Short Interest
17,700 shares
Previous Short Interest
10,400 shares
Change Vs. Previous Month
+70.19%
Dollar Volume Sold Short
$52,038.00
Short Interest Ratio
1.1 Days to Cover
Last Record Date
October 31, 2024
Outstanding Shares
2,230,000 shares
Float Size
1,960,000 shares
Short Percent of Float
0.90%
Today's Trading Volume
641 shares
Average Trading Volume
398,508 shares
Today's Volume Vs. Average
0%
Short Selling GT Biopharma?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for GT Biopharma and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

GTBP Short Interest Over Time

GTBP Days to Cover Over Time

GTBP Percentage of Float Shorted Over Time

GT Biopharma Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/31/202417,700 shares $52,038.00 +70.2%0.9%1.1 $2.94
10/15/202410,400 shares $20,696.00 +108.0%0.5%0.7 $1.99
9/30/20245,000 shares $11,545.00 -35.9%0.2%0.4 $2.31
9/15/20247,800 shares $17,004.00 -16.1%0.4%0.3 $2.18
8/31/20249,300 shares $19,995.00 -51.8%0.4%0.3 $2.15
8/15/202419,300 shares $44,390.00 +14.9%0.9%0.5 $2.30
7/31/202416,800 shares $43,848.00 +1.8%0.8%0 $2.61
7/15/202416,500 shares $46,695.00 -61.6%0.8%0 $2.83
6/30/202443,000 shares $121,690.00 +34.4%2.1%0 $2.83
6/15/202432,000 shares $92,480.00 -11.1%1.6%0 $2.89
5/31/202436,000 shares $135,000.00 +1,233.3%1.8%0 $3.75
5/15/20242,700 shares $8,235.00 -55.0%0.2%0 $3.05
4/30/20246,000 shares $18,000.00 +81.8%0.5%0.5 $3.00
4/15/20243,300 shares $12,408.00 -62.5%0.3%0.3 $3.76
3/31/20248,800 shares $38,984.00 +79.6%0.7%0.7 $4.43
3/15/20244,900 shares $22,687.00 -14.0%0.4%0.4 $4.63
2/29/20245,700 shares $24,282.00 +72.7%0.5%0.6 $4.26
2/15/20243,300 shares $13,200.00 +312.5%0.3%0.4 $4.00
1/31/2024800 shares $4,752.00 -98.6%0.1%0.1 $5.94
1/15/202458,800 shares $13,171.20 +150.2%0.2%0.4 $0.22
12/31/202323,500 shares $5,992.50 -64.8%0.1%0.2 $0.26
12/15/202366,800 shares $16,472.88 +14.8%0.2%0.6 $0.25
11/30/202358,200 shares $12,804.00 -62.3%0.2%0.5 $0.22
11/15/2023154,300 shares $37,032.00 +16.1%0.4%1.2 $0.24
10/31/2023132,900 shares $33,278.16 -16.8%0.4%0.9 $0.25
10/15/2023159,800 shares $40,749.00 +56.4%0.4%1 $0.26
9/30/2023102,200 shares $24,640.42 +122.2%0.3%0.4 $0.24
9/15/202346,000 shares $12,880.00 -12.9%0.1%0.1 $0.28
8/31/202352,800 shares $13,780.80 -76.7%0.1%0.1 $0.26
8/15/2023227,000 shares $59,996.10 +22.3%0.6%0.4 $0.26
7/31/2023185,600 shares $51,040.00 -15.6%0.5%0.3 $0.28
7/15/2023219,900 shares $73,402.62 -1.7%0.6%0.4 $0.33
6/30/2023223,600 shares $69,763.20 +9.3%0.6%0.4 $0.31
6/15/2023204,600 shares $71,589.54 +53.5%0.6%0.5 $0.35
5/31/2023133,300 shares $30,019.16 -5.7%0.4%0.5 $0.23
5/15/2023141,400 shares $42,391.72 -12.8%0.4%0.9 $0.30
1/29/2021102,800 shares $47,550.14 +411.4%N/A0.1 $0.46
1/15/202127,100 shares $13,818.29 +118.6%N/A0 $0.51
12/31/202010,200 shares $4,386.00 -62.4%N/A0 $0.43
12/15/202027,100 shares $7,859.00 +118.6%N/A0 $0.29
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

11/30/202012,400 shares $2,168.76 -34.7%N/A0 $0.17
11/15/202019,000 shares $3,467.50 -54.2%N/A0 $0.18
10/30/202041,500 shares $8,590.50 +24.3%N/A0.1 $0.21
10/15/202033,400 shares $6,680.00 +59.8%N/A0 $0.20
9/30/202020,900 shares $3,657.50 +770.8%N/A0.1 $0.18
9/15/20202,400 shares $408.00 -81.5%N/A0 $0.17
8/31/202013,000 shares $2,382.90 +20.4%N/A0.1 $0.18
8/14/202010,800 shares $1,922.40 -26.5%N/A0 $0.18
7/31/202014,700 shares $2,940.00 -30.7%N/A0 $0.20
7/15/202021,200 shares $4,452.00 -0.5%N/A0.1 $0.21
6/30/202021,300 shares $2,982.00 -47.4%N/A0.1 $0.14
6/15/202040,500 shares $8,505.00 +130.1%N/A0.3 $0.21
5/29/202017,600 shares $3,560.48 +175.0%N/A0.1 $0.20
5/15/20206,400 shares $1,312.00 -72.5%N/A0 $0.21
4/30/202023,300 shares $3,259.67 +870.8%N/A0.3 $0.14
4/15/20202,400 shares $360.00 -41.5%N/A0 $0.15
3/31/20204,100 shares $627.30 -93.6%N/A0 $0.15
3/13/202063,900 shares $11,502.00 +2,562.5%N/A0.1 $0.18
2/28/20202,400 shares $235.20 No ChangeN/A0 $0.10
2/14/20202,400 shares $228.72 -67.1%N/A0 $0.10
1/31/20207,300 shares $740.22 +204.2%N/A0 $0.10
1/15/20202,400 shares $240.00 -79.5%N/A0 $0.10
12/31/201911,700 shares $1,170.00 +9.4%N/A0 $0.10

GTBP Short Interest - Frequently Asked Questions

What is GT Biopharma's current short interest?

Short interest is the volume of GT Biopharma shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 17,700 shares of GTBP short. 0.90% of GT Biopharma's shares are currently sold short. Learn More on GT Biopharma's current short interest.

What is a good short interest ratio for GT Biopharma?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GTBP shares currently have a short interest ratio of 1.0. Learn More on GT Biopharma's short interest ratio.

Which institutional investors are shorting GT Biopharma?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of GT Biopharma: DekaBank Deutsche Girozentrale. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for GT Biopharma?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.90% of GT Biopharma's floating shares are currently sold short.

Is GT Biopharma's short interest increasing or decreasing?

GT Biopharma saw a increase in short interest in October. As of October 31st, there was short interest totaling 17,700 shares, an increase of 70.2% from the previous total of 10,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is GT Biopharma's float size?

GT Biopharma currently has issued a total of 2,230,000 shares. Some of GT Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. GT Biopharma currently has a public float of 1,960,000 shares.

How does GT Biopharma's short interest compare to its competitors?

0.90% of GT Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to GT Biopharma: Jaguar Health, Inc. (4.31%), Kiora Pharmaceuticals, Inc. (1.76%), Natural Alternatives International, Inc. (0.17%), DURECT Co. (3.35%), Marker Therapeutics, Inc. (1.09%), Longeveron Inc. (28.01%), Lipocine Inc. (1.45%), GeoVax Labs, Inc. (3.19%), Lakeshore Biopharma Co., Ltd. (0.42%), Equillium, Inc. (0.68%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

What does it mean to sell short GT Biopharma stock?

Short selling GTBP is an investing strategy that aims to generate trading profit from GT Biopharma as its price is falling. GTBP shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against GT Biopharma?

A short squeeze for GT Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GTBP, which in turn drives the price of the stock up even further.

How often is GT Biopharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTBP, twice per month. The most recent reporting period available is October, 31 2024.




This page (NASDAQ:GTBP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners